The clinical significance and therapeutic implications of extraprostatic invasion

Surgical Oncology

Volumn 18, Issue 3, 2009, Pages 203-212

  Foley, Charlotte L ^a   Feneley, Mark R ^b  

^a WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Multimodality treatment; Prostate cancer; Radical prostatectomy; Radiotherapy; Stage T3; Staging

Indexed keywords

BICALUTAMIDE; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RELIABILITY; REVIEW; SEMINAL VESICLE; TREATMENT FAILURE;

COMBINED MODALITY THERAPY; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; SEMINAL VESICLES;

EID: 68849121494     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2009.03.004     Document Type: Review

References (94)

1. Bader P., Burkhard F.C., Markwalder R., and Studer U.E. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?. J Urol 169 (2003) 849-854
2. Bates T.S., Gillatt D.A., Cavanagh P.M., and Speakman M. A comparison of endorectal magnetic resonance imaging and transrectal ultrasonography in the local staging of prostate cancer with histopathological correlation. Br J Urol 79 (1997) 927-932
3. Beard C., Schultz D., Loffredo M., Cote K., Renshaw A.A., Hurwitz M.D., et al. Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 66 (2006) 403-407
4. Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., and Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26 (2008) 242-245
5. Bismar T.A., Lewis Jr. J.S., Vollmer R.T., and Humphrey P.A. Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population. Am J Surg Pathol 27 (2003) 432-440
6. Blute M.L., Bostwick D.G., Bergstralh E.J., Slezak J.M., Martin S.K., Amling C.L., et al. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology 50 (1997) 733-739
7. Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-106
8. Bolla M., van Poppel H., Collette L., van Cangh P., Vekemans K., Da Pozzo L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
9. Burkhard F.C., Bader P., Schneider E., Markwalder R., and Studer U.E. Reliability of preoperative values to determine the need for lymphadenectomy in patients with prostate cancer and meticulous lymph node dissection. Eur Urol 42 (2002) 84-90
10. Carver B.S., Bianco Jr. F.J., Scardino P.T., and Eastham J.A. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J Urol 176 (2006) 564-568
11. Connolly S.S., O'Malley K.J., O'Brien A., Kelly D.G., Mulvin D.W., and Quinlan D.M. Can prostate biopsies predict suitability for nerve-sparing radical prostatectomy?. Scand J Urol Nephrol 38 3 (2004) 216-220
12. Cooperberg M.R., Lubeck D.P., Mehta S.S., and Carroll P.R. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 170 (2003) S21-S27
13. D'Amico A.V., Whittington R., Malkowicz S.B., Schultz D., Blank K., Broderick G.A., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
14. Dearnaley D.P., Khoo V.S., Norman A.R., Meyer L., Nahum A., Tait D., et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353 (1999) 267-272
15. Denberg T.D., Glode L.M., Steiner J.F., Crawford E.D., and Hoffman R.M. Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma. BJU Int 98 (2006) 335-340
16. Derweesh I.H., Kupelian P.A., Zippe C., Levin H.S., Brainard J., Magi-Galluzi C., et al. Continuing trends in pathological stage migration in radical prostatectomy specimens. Urol Oncol 22 (2004) 300-306
17. Eastham J.A., Kuroiwa K., Ohori M., Serio A.M., Gorbonos A., Maru N., et al. Prognostic significance of location of positive margins in radical prostatectomy specimens. Urology 70 (2007) 965-969
18. Eichelberg C., Erbersdobler A., Haese A., Schlomm T., Chun F.K., Currlin E., et al. Frozen section for the management of intraoperatively detected palpable tumor lesions during nerve-sparing scheduled radical prostatectomy. Eur Urol 49 (2006) 1011-1016
19. Epstein J.I., Carmichael M., and Walsh P.C. Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis. J Urol 149 (1993) 1040-1045
20. Epstein J.I., Pizov G., and Walsh P.C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71 (1993) 3582-3593
21. Epstein J.I., Partin A.W., Sauvageot J., and Walsh P.C. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 20 (1996) 286-294
22. Epstein J.I., Partin A.W., Potter S.R., and Walsh P.C. Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. Urology 56 (2000) 283-288
23. Freedland S.J., Partin A.W., Humphreys E.B., Mangold L.A., and Walsh P.C. Radical prostatectomy for clinical stage T3a disease. Cancer 109 (2007) 1273-1278
24. Fütterer J.J., Engelbrecht M.R., Jager G.J., Hartman R.P., King B.F., Hulsbergen-Van de Kaa C.A., et al. Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils. Local staging accuracy of prostate cancer using endorectal coil MR imaging. Eur Radiol 17 (2007) 1055-1065
25. Gancarczyk K.J., Wu H., McLeod D.G., Kane C., Kusuda L., Lance R., et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology 61 (2003) 589-595
26. Gerber G.S., Thisted R.A., Chodak G.W., Schroder F.H., Frohmuller H.G., Scardino P.T., et al. Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. Eur Urol 32 (1997) 385-390
27. Graefen M., Haese A., Pichlmeier U., Hammerer P.G., Noldus J., Butz K., et al. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol 165 (2001) 857-863
28. Grossfeld G.D., Tigrani V.S., Nudell D., Roach III M., Weinberg V.K., Presti Jr. J.C., et al. Management of a positive surgical margin after radical prostatectomy: decision analysis. J Urol 164 (2000) 93-99
29. Guillonneau B., Debras B., Veillon B., Bougaran J., Chambon E., and Vallancien G. Indications for preoperative seminal vesicle biopsies in staging of clinically localized prostatic cancer. Eur Urol 32 (1997) 160-165
30. Hamper U.M., Sheth S., Walsh P.C., Holtz P.M., and Epstein J.I. Carcinoma of the prostate: value of transrectal sonography in detecting extension into the neurovascular bundle. AJR Am J Roentgenol 155 (1990) 1015-1019
31. Harnden P., Shelley M.D., Clements H., Coles B., Tyndale-Biscoe R.S., Naylor B., et al. The prognostic significance of perineural invasion in prostatic cancer biopsies: a systematic review. Cancer 109 (2007) 13-24
32. Hsu C.Y., Joniau S., Oyen R., Roskams T., and Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 51 (2007) 121-128
33. Hull G.W., Rabbani F., Abbas F., Wheeler T.M., Kattan M.W., and Scardino P.T. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167 (2002) 528-534
34. Johnson C.W., Anastasiadis A.G., McKiernan J.M., Salomon L., Eaton S., Goluboff E.T., et al. Prognostic indicators for long term outcome following radical retropubic prostatectomy for prostate cancer involving the seminal vesicles. Urol Oncol 22 (2004) 107-111
35. Joniau S., Hsu C.Y., Lerut E., Van Baelen A., Haustermans K., Roskams T., et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 51 (2007) 388-394
36. Joniau S., and Van Poppel H. Localized prostate cancer: can we better define who is at risk of unfavourable outcome?. BJU Int 101 S2 (2008) 5-10
37. Kälkner K.M., Wahlgren T., Ryberg M., Cohn-Cedermark G., Castellanos E., Zimmerman R., et al. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up. Acta Oncol 46 (2007) 909-917
38. Kattan M.W., Eastham J.A., Stapleton A.M., Wheeler T.M., and Scardino P.T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766-771
39. Kattan M.W., Zelefsky M.J., Kupelian P.A., Scardino P.T., Fuks Z., and Leibel S.A. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18 (2000) 3352-3359
40. Kattan M.W. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol 13 (2003) 111-116
41. Koh H., Kattan M.W., Scardino P.T., Suyama K., Maru N., Slawin K., et al. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol 170 (2003) 1203-1208
42. Lee H.H., Warde P., and Jewett M.A. Neoadjuvant hormonal therapy in carcinoma of the prostate. BJU Int 83 (1999) 438-448
43. Lee H.M., Solan M.J., Lupinacci P., Gomella L.G., and Valicenti R.K. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy. Urology 64 (2004) 84-89
44. Lee I.H., Roberts R., Shah R.B., Wojno K.J., Wei J.T., and Sandler H.M. Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer. Int J Radiat Oncol Biol Phys. 68 (2007) 1059-1064
45. Lerner S.E., Blute M.L., and Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 154 (1995) 1447-1452
46. Loeb S., Smith N.D., Roehl K.A., and Catalona W.J. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 69 (2007) 1170-1175
47. Lowe B.A., and Leiberman S.F. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy. J Urol 158 (1997) 1452-1456
48. Makarov D.V., Trock B.J., Humphreys E.B., Mangold L.A., Walsh P.C., Epstein J.I., et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69 (2007) 1095-1101
49. Masterson T.A., Pettus J.A., Middleton R.G., and Stephenson R.A. Isolated seminal vesicle invasion imparts better outcomes after radical retropubic prostatectomy for clinically localized prostate cancer: prognostic stratification of pt3b disease by nodal and margin status. Urology 66 (2005) 152-155
50. McLeod D.G., Iversen P., See W.A., Morris T., Armstrong J., Wirth M.P., et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 97 (2006) 247-254
51. Morgan W.R., Zincke H., Rainwater L.M., Myers R.P., and Klee G.G. Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation). J Urol 145 (1991) 319-323
52. Nudell D.M., Grossfeld G.D., Weinberg V.K., Roach III M., and Carroll P.R. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 54 (1999) 1049-1057
53. Obek C., Louis P., Civantos F., and Soloway M.S. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. J Urol 161 (1999) 494-498
54. Ohori M., Kattan M.W., Koh H., Maru N., Slawin K.M., Shariat S., et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 171 (2004) 1844-1849
55. Ohori M., Wheeler T.M., Kattan M.W., Goto Y., and Scardino P.T. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154 (1995) 1818-1824
56. Palisaar R.J., Noldus J., Graefen M., Erbersdobler A., Haese A., and Huland H. Influence of nerve-sparing (NS) procedure during radical prostatectomy (RP) on margin status and biochemical failure. Eur Urol 47 (2005) 176-184
57. Parker C., Clarke N., Logue J., Payne H., Catton C., Kynaston H., et al., The RADICALS Trial Management Group. RADICALS (radiotherapy and androgen deprivation in combination after local surgery). Clin Oncol (R Coll Radiol) 19 3 (2007 Apr) 167-171
58. Partin A.W., Carter H.B., Chan D.W., Epstein J.I., Oesterling J.E., Rock R.C., et al. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143 (1990) 747-752
59. Partin A.W., Yoo J., Carter H.B., Pearson J.D., Chan D.W., Epstein J.I., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110-114
60. Partin A.W., Kattan M.W., Subong E.N., Walsh P.C., Wojno K.J., Oesterling J.E., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277 (1997) 1445-1451
61. Partin A.W., Mangold L.A., Lamm D.M., Walsh P.C., Epstein J.I., and Pearson J.D. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (2001) 843-848
62. Petrylak D.P., Tangen C.M., Hussain M.H., Lara Jr. P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
63. Pilepich M.V., Winter K., Lawton C.A., Krisch R.E., Wolkov H.B., Movsas B., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
64. Porter C.R., Kodama K., Gibbons R.P., Correa Jr. R., Chun F.K., Perrotte P., et al. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol 176 (2006) 569-574
65. Pound C.R., Partin A.W., Epstein J.I., and Walsh P.C. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 24 (1997) 395-406
66. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
67. Ravery V., Boccon-Gibod L.A., Dauge-Geffroy M.C., Billebaud T., Delmas V., Meulemans A., et al. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 44 (1994) 371-376
68. Rifkin M.D., Zerhouni E.A., Gatsonis C.A., Quint L.E., Paushter D.M., Epstein J.I., et al. Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial. N Engl J Med 323 (1990) 621-626
69. Roach III M., Bae K., Speight J., Wolkov H.B., Rubin P., Lee R.J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26 (2008) 585-591
70. Rodriguez-Covarrubias F., Larré S., Dahan M., De La Taille A., Allory Y., Yiou R., et al. Invasion of bladder neck after radical prostatectomy: one definition for different outcomes. Prostate Cancer Prostatic Dis 11 (2008) 294-297
71. Rubin M.A., Bassily N., Sanda M., Montie J., Strawderman M.S., and Wojno K. Relationship and significance of greatest percentage of tumor and perineural invasion on needle biopsy in prostatic adenocarcinoma. Am J Surg Pathol 24 (2000) 183-189
72. Salomon L., Anastasiadis A.G., Johnson C.W., McKiernan J.M., Goluboff E.T., Abbou C.C., et al. Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression. Urology 62 (2003) 304-309
73. Schild S.E. Radiation therapy (RT) after prostatectomy: the case for salvage therapy as opposed to adjuvant therapy. Int J Cancer 96 (2001) 94-98
74. Smith R.C., Partin A.W., Epstein J.I., and Brendler C.B. Extended followup of the influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation. J Urol 156 (1996) 454-457
75. Soloway M.S., Pareek K., Sharifi R., Wajsman Z., McLeod D., Wood Jr. D.P., et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 167 (2002) 112-116
76. Stamey T.A., Kabalin J.N., McNeal J.E., Johnstone I.M., Freiha F., Redwine E.A., et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 141 (1989) 1076-1083
77. Stamey T.A., Villers A.A., McNeal J.E., Link P.C., and Freiha F.S. Positive surgical margins at radical prostatectomy: importance of the apical dissection. J Urol 143 (1990) 1166-1172
78. Swindle P., Eastham J.A., Ohori M., Kattan M.W., Wheeler T., Maru N., et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 174 (2005) 903-907
79. Terris M.K., McNeal J.E., Freiha F.S., and Stamey T.A. Efficacy of transrectal ultrasound-guided seminal vesicle biopsies in the detection of seminal vesicle invasion by prostate cancer. J Urol 149 (1993) 1035-1039
80. Thompson Jr. I.M., Tangen C.M., Paradelo J., Lucia M.S., Miller G., Troyer D., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomised clinical trial. JAMA 296 (2006) 2329-2335
81. Vallancien G., Bochereau G., Wetzel O., Bretheau D., Prapotnich D., and Bougaran J. Influence of preoperative positive seminal vesicle biopsy on the staging of prostatic cancer. J Urol 152 (1994) 1152-1156
82. Van den Ouden D., Hop W.C., and Schroder F.H. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 160 (1998) 1392-1397
83. Van der Kwast T.H., Bolla M., Van Poppel H., Van Cangh P., Vekemans K., Da Pozzo L., et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25 (2007) 4178-4186
84. Van Poppel H., Vekemans K., Da Pozzo L., Bono A., Kliment J., Montironi R., et al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur J Cancer 42 (2006) 1062-1067
85. Vora S.A., Wong W.W., Schild S.E., Ezzell G.A., and Halyard M.Y. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 1053-1058
86. Walsh P.C., and Donker P.J. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 128 (1982) 492-497
87. Walsh P.C., Partin A.W., and Epstein J.I. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 152 (1994) 1831-1836
88. Ward J.F., Zincke H., Bergstralh E.J., Slezak J.M., Myers R.P., and Blute M.L. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol 172 (2004) 1328-1332
89. Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., and Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 95 (2005) 751-756
90. Weider J.A., and Soloway M.S. Incidence, etiology, location, prevention and treatment of positive surgical margins after radical prostatectomy for prostate cancer. J Urol 160 (1998) 299-315
91. Weight C.J., Ciezki J.P., Reddy C.A., Zhou M., and Klein E.A. Perineural invasion on prostate needle biopsy does not predict biochemical failure following brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 65 (2006) 347-350
92. Yossepowitch O., Sircar K., Scardino P.T., Ohori M., Kattan M.W., Wheeler T.M., et al. Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor. J Urol 168 (2002) 2011-2015
93. Yu H.H., Song D.Y., Tsai Y.Y., Thompson T., Frassica D.A., and DeWeese T.L. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy. Urology 70 (2007) 111-116
94. Zelefsky M.J., Yamada Y., Fuks Z., Zhang Z., Hunt M., Cahlon O., et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71 (2008) 1028-1033